HLB's Elevar Submits Bile Duct Cancer Drug Lirafugratinib for EU Approval

Elevar Therapeutics, a subsidiary of Korean biopharmaceutical firm HLB, has submitted a marketing authorization application to the European Medicines Agency (EMA) for lirafugratinib. This drug is proposed as a second-line treatment for advanced or metastatic cholangiocarcinoma (bile duct cancer) with specific genetic alterations. The filing is supported by positive data from the global Phase 1/2 ReFocus trial.